Cumulus Neuroscience Appoints Dr Ian Campbell to Board of Directors

First published: 17th June 2021

Ian Campbell board of director

Ian Campbell, Ph.D., Director, Cumulus Neuroscience

Cumulus Neuroscience announces that Dr Ian Campbell has been appointed to the Board of Directors.

Ian has over 15 years of executive experience in the Health and Life Sciences sector. He is currently Chief Business Officer at LifeArc, one of Cumulus’ investors, where he leads the research charity’s Business and Development Partnerships, translating Life Science innovation into tangible benefits for patients.

From 2018-2020 Ian worked as interim Chair of Innovate UK (IUK), and before that as Director for Health and Life Sciences. IUK is part of UK Research and Innovation (UKRI), who fund and support businesses to drive innovation and research development across all economic sectors, value chains and UK regions. Ian has also served as Director for IUK’s Ageing Society, Health and Nutrition Initiative where he gained extensive entrepreneurial and business experience in the Healthcare and Life Science sector.

Prior to this, Ian was CEO for Arquer Diagnostics, a company developing and commercialising non-invasive immunoassay tests for cancers of the urogenital tract, and before that occupied several senior leadership roles in the biotech industry.

Cumulus Neuroscience CEO Ronan Cunningham commented: “We are delighted to welcome Ian to the Board of Directors. His strong leadership and tremendous experience transforming progressive companies within the Healthcare industry will be invaluable in supporting Cumulus Neuroscience. With his combined commercial and technical background, Ian will play a crucial role in the future development and application of our technologies.”

Dr Ian Campbell, newly appointed Director, added: “With CNS disorders becoming increasingly prevalent, companies like Cumulus Neuroscience are more vital than ever for helping to progress new treatments. I am very impressed by the company’s next-generation integrated technologies offering the potential to accelerate the development of new dementia treatments by accessing robust and meaningful real-world clinical data faster and more cost-effectively.”